SHH and neoplasm: The main highlight of this research is the demonstration that the inhibition of the SHH pathway using vismodegib, a well-established SMO inhibitor used in the clinic (De Smaele et al. 2010), results in premature tumour formation and increased tumour cell proliferation in both genetically engineered and patient-derived xenograft mouse models.